Antibiotic-induced gut microbiota dysbiosis altered host metabolism†

IF 3 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular omics Pub Date : 2023-02-28 DOI:10.1039/D2MO00284A

Mengxue He, Jiachen Shi, Aiyang Liu, Yong-Jiang Xu and Yuanfa Liu

引用次数: 1

Abstract

Antibiotics are useful for treating infections caused by bacteria, but they have negative effects on the host body. The goal of this study was to determine whether antibiotics alter the metabolic phenotype of the host. We found that taking antibiotics reduced the diversity and richness of gut microbiota and affected the composition of the microbiome, which in turn altered the metabolic profiles of plasma and fecal samples. Additionally, plasma and fecal metabolites and gut microbiota genera showed a significant association. The most significant pathways related to the gut dysbiosis induced by antibiotics including purine, pentose, and glucuronate metabolism, histidine, ascorbate and alternate, lysine degradation, and fatty acid biosynthesis. The relationship between gut microbiota and altered metabolites of plasma and feces provides information about bacterial action, which is useful for designing new microbiota-based disease prevention and treatment interventions.

Abstract Image

查看原文本刊更多论文

抗生素诱导的肠道菌群失调改变了宿主代谢†

抗生素对治疗细菌引起的感染是有用的，但对宿主身体有负面影响。本研究的目的是确定抗生素是否会改变宿主的代谢表型。我们发现，服用抗生素降低了肠道微生物群的多样性和丰富度，并影响了微生物群的组成，从而改变了血浆和粪便样本的代谢谱。此外，血浆和粪便代谢物与肠道菌群属有显著相关性。与抗生素引起的肠道生态失调相关的最重要途径包括嘌呤、戊糖和葡萄糖酸盐代谢、组氨酸、抗坏血酸和替代、赖氨酸降解和脂肪酸生物合成。肠道微生物群与血浆和粪便代谢产物改变之间的关系提供了细菌作用的信息，这对设计新的基于微生物群的疾病预防和治疗干预措施是有用的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular omics Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

5.40

自引率

3.40%

发文量

期刊介绍： Molecular Omics publishes high-quality research from across the -omics sciences. Topics include, but are not limited to: -omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance -omics studies for clinical applications with validation, such as finding biomarkers for diagnostics or potential new drug targets -omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques -studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field. Molecular Omics only accepts articles of high importance and interest that provide significant new insight into important chemical or biological problems. This could be fundamental research that significantly increases understanding or research that demonstrates clear functional benefits. Papers reporting new results that could be routinely predicted, do not show a significant improvement over known research, or are of interest only to the specialist in the area are not suitable for publication in Molecular Omics.